Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.23.1
License Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2015
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Feb. 28, 2023
USD ($)
Jan. 31, 2019
USD ($)
May 31, 2016
USD ($)
item
License Agreements              
Revenue recognition milestone revenue recognized     $ 21,000        
Research and development              
License Agreements              
Value of common stock shares issued       $ 1,900,000      
NeuPharma, Inc. | Additional sales milestone              
License Agreements              
Maximum potential milestone payments $ 40,000,000.0            
NeuPharma, Inc. | Clinical and Development Milestone              
License Agreements              
Maximum potential milestone payments 39,000,000.0            
NeuPharma, Inc. | Regulatory Approvals To Commercialize The Products              
License Agreements              
Maximum potential milestone payments 22,500,000            
Dana-Farber Cancer Institute              
License Agreements              
Maintenance fee 50,000            
Dana-Farber Cancer Institute | First commercial sale milestone              
License Agreements              
Maximum potential milestone payments 21,500,000            
Dana-Farber Cancer Institute | Additional sales milestone              
License Agreements              
Maximum potential milestone payments $ 60,000,000.0            
Revenue recognition milestone payments   $ 60,000,000.0          
Jubilant Biosys Limited | Additional sales milestone              
License Agreements              
Maximum potential milestone payments             $ 89,300,000
Jubilant Biosys Limited | Clinical and Development Milestone              
License Agreements              
Maximum potential milestone payments             88,400,000
Jubilant Biosys Limited | Regulatory Approvals To Commercialize The Products              
License Agreements              
Maximum potential milestone payments             $ 59,500,000
Adimab, LLC | PD-L1 | Research and development              
License Agreements              
Non-Refundable milestone payment         $ 2,200,000    
Adimab, LLC | Clinical and Development Milestone              
License Agreements              
Maximum potential milestone payments           $ 2,500,000  
Collaboration Agreement With TGTX              
License Agreements              
Revenue recognition milestone revenue recognized   29,000 $ 31,000        
Collaboration Agreement With TGTX | First commercial sale milestone | PD-L1              
License Agreements              
Revenue recognition milestone payments   27,600,000          
Collaboration Agreement With TGTX | First commercial sale milestone | PD-L1 GITR              
License Agreements              
Revenue recognition milestone payments   21,500,000          
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1 GITR              
License Agreements              
Revenue recognition milestone payments   7,000,000.0          
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1              
License Agreements              
Revenue recognition milestone payments   19,200,000          
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1 GITR              
License Agreements              
Revenue recognition milestone payments   14,500,000          
Collaboration Agreement With TGTX | Clinical Development and Regulatory Milestones | PD-L1              
License Agreements              
Revenue recognition milestone payments   8,400,000          
Sublicense Agreement with TGTX              
License Agreements              
Research and development cost             50.00%
Number of clinical development milestones | item             3
Number of licensed products | item             2
Sublicense Agreement with TGTX | Additional sales milestone              
License Agreements              
Revenue recognition milestone payments             $ 89,300,000
Sublicense Agreement with TGTX | Clinical and Development Milestone              
License Agreements              
Revenue recognition milestone payments             25,500,000
Sublicense Agreement with TGTX | Five Regulatory Approvals And First Commercial Sales              
License Agreements              
Revenue recognition milestone payments             61,900,000
Sublicense Agreement with TGTX | Clinical Development and Regulatory Milestones              
License Agreements              
Revenue recognition milestone payments             $ 87,400,000
Collaboration Agreement With GITR              
License Agreements              
Revenue recognition milestone revenue recognized   $ 6,000